Sevacizumab

Drug Profile

Sevacizumab

Alternative Names: Anti-VEGF monoclonal antibody - Apexigen; APX-003; BD-0801; EPI-0030; SIM-BD-0801; TK 001

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator Epitomics
  • Developer Apexigen; Jiangsu T-mab BioPharma; Simcere Pharmaceutical Group
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Solid tumours
  • Phase I Wet age-related macular degeneration
  • Preclinical Cancer

Most Recent Events

  • 11 Nov 2016 Phase-II clinical trials in Colorectal cancer in China (Parenteral) (Apexigen pipeline, November 2016)
  • 11 Nov 2016 Phase-II clinical trials in Solid tumours in China (Parenteral) (Apexigen pipeline, November 2016)
  • 01 Nov 2015 Phase-I clinical trials in Wet age-related macular degeneration (In adults, In the elderly) in China (Intravitreous) (NCT02613559)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top